Back to Studies
P1113 / AERAS-404 TB Vaccine in BCG-Primed Infants
Phase I/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants
Closed to Follow Up
Primary Protocol Team Members
P1113 is a Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study of the AERAS-404 tuberculosis vaccine in HIV-unexposed, HIV-uninfected, BCG-primed South African infants. The study is being conducted in collaboration with AERAS, Sanofi Pasteur, and Statens Serum Institut.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...